Navigation Links
Gleevec Pushes Advanced Melanoma Into Remission
Date:4/17/2008

Woman's case first showing the cancer may have an Achilles' heel, report suggests

THURSDAY, April 17 (HealthDay News) -- The cancer drug Gleevec has forced metastatic melanoma into remission for the first time, report researchers at the Dana-Farber Cancer Institute in Boston.

The case involves a 79-year-old woman with melanoma tumors in several parts of her abdomen. The tumor cells carried an abnormality in a gene called KIT, so the patient was enrolled in a clinical trail of the drug imatinib (Gleevec), which targets the KIT gene.

Four weeks after the woman started therapy, there was dramatic reduction in tumor size and metabolism. Two of the tumor masses had vanished, and several others were much smaller. After four months, the tumors were still in check and, nine months later, the women was still taking the drug and her condition remained stable.

The report was published in the April 20 issue of the Journal of Clinical Oncology.

"This is the first proof of principle that we can find an Achilles' heel in melanoma and by targeting that gene with a drug, cause the [tumor cells] to die. It is especially exciting because there haven't been any effective treatments for melanoma patients with metastatic disease," study author Dr. Stephen Hodi said in a prepared statement.

He said this case may involve just one patient, but should inspire new hope in the fight against melanoma. Because previous research failed to identify any genetic weak point that could be targeted to stop melanoma cell growth, some researchers believed that no such Achilles' heel existed for melanoma cells. The discovery of this one suggests there may be others.

"Dramatic remissions in metastatic melanoma are something that, as physicians, we've rarely seen. Confirming these results will require enrolling additional patients in clinical trials -- something we're actively working to accomplish," Hodi said.

More information

The U.S. National Cancer Institute has more about melanoma.



-- Robert Preidt



SOURCE: Dana-Farber Cancer Institute, news release, April 17, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Gleevec May Disrupt Ovarian Function
2. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
3. Gleevec, the targeted cancer pill, delivers more good news to patients
4. Arizona Senate Pushes for Smoking Cessation Treatments for State Medicaid Beneficiaries
5. Pedometer Pushes People to Walk More
6. Depression Pushes Middle-Aged Workers to Retire
7. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
8. HHS Names First Director of the Biomedical Advanced Research Development Authority
9. Advanced Life Sciences to Host Conference Call to Discuss April 7th Meeting with FDA
10. Cato Research Ltd. and Advanced Targeting Systems, Inc. Partner to Develop SP-SAP for Chronic Pain
11. Body Mass Index may serve as prognostic tool for advanced, aggressive breast cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
(Date:4/28/2017)... ... April 28, 2017 , ... NuevaCare, a leading home ... as Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to its ... bookmark and read organized content on topics such as home care (generally) as well ...
(Date:4/27/2017)... ... April 27, 2017 , ... Today, ... based in Denver, Colorado, announced an agreement to create the Jane and Leonard ... of the Jane and Leonard Korman Family Foundation. The collaboration leverages the strengths ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... , April 19, 2017 Global ... This report on the prostate cancer therapeutics market ... global market. Increasing prevalence of prostate cancer, launch ... in the development of new drugs & therapeutic ... cancer drug due to lesser side effects are ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence ... advanced Parkinson,s, according to a study released today that will ... Annual Meeting in Boston , April ... to the treatment of Parkinson,s disease, the oral drug levodopa ... life and longevity. But as the disease progresses, the effects ...
Breaking Medicine Technology: